Navigation Links
MedImmune Focused on Revolutionizing Cancer Care
Date:11/16/2010

GAITHERSBURG, Md., Nov. 16, 2010 /PRNewswire/ -- Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

"At MedImmune, we are thinking about cancer and treatment in new ways, using insights and understanding of the disease to discover breakthrough biologic therapies that can be used to treat specific cancers for the individual patient," said Jerry McMahon, Senior Vice President and Oncology Innovative Medicines Unit Leader.  "We are excited about the progress of the oncology portfolio and are looking forward to its advancement of multiple oncology products into expanded clinical studies in the near future."  

With innovative antibody and biologic technologies, the MedImmune Oncology pipeline is focusing on developing new therapies to eliminate cancer cells in more effective and targeted ways.  This research is addressing the key areas critical to the development and progression of cancer: immune-mediated killing, vascular modulation, growth factor, and survival signaling.  

"The identification of novel cancer drug targets and associated biologic markers has not only altered the way we view cancer, but is truly revolutionizing our standard of care," said Bahija Jallal, Executive Vice President Research and Development at MedImmune.  "It is this research, with products like moxetumomab pasudotox (CAT-8015), that will help develop more effective solutions to targeting malignant tumor cells and providing a more personalized approach to medicine."

New data presentations

Four MedImmune-sponsored posters are being presented at the 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" starting on Tuesday, November 16 in Berlin.  EORTC-NCI-AACR is a joint meeting of the European Organisation for Research and Treatment of Cancer, the National Cance
'/>"/>

SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
2. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
3. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
4. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
5. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
6. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
7. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
8. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
9. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
11. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Tasly Pharmaceuticals, Inc., the world,s leader in ... the launch of Deepure. Deepure is ... and women concerned with supporting their overall health ... while helping keep their health care cost down.  ... formulas, namely, ProHeart PLUS, ImmunoPower PLUS, and Pro-Memory ...
(Date:9/30/2014)... 2014 Aileron Therapeutics, Inc. - Product ... Markets Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline ... Aileron Therapeutics, Inc.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... , September 30, 2014 ... research report the "Glycobiology/Glycomics Market by Product [Enzymes ... MALDI-TOF), Kits, and Reagents], Application (Immunology, Oncology) ... to 2019", published by MarketsandMarkets, provides a ... challenges, opportunities, current market trends, and strategies ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... Orally Dissolving Film StripBioAlliance to Resubmit Loramyc(R) NDA WOODCLIFF ... products division of a wholly owned subsidiary of Par ... provides an update on two of its pipeline products. ... 7, 2009, Strativa submitted a New Drug Application (NDA) ...
... April 8 Phase III data, published online this ... Metabolism , showed that arzoxifene, an investigational selective estrogen ... Company (NYSE: LLY ), significantly increased lumbar ... postmenopausal women with normal or low bone mass, versus ...
Cached Medicine Technology:Strativa Pharmaceuticals Provides Product Pipeline Update 2Strativa Pharmaceuticals Provides Product Pipeline Update 3Strativa Pharmaceuticals Provides Product Pipeline Update 4Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 2Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 4
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- There,s no ... prevent type 2 diabetes, a new study says. ... vitamin D might protect people against type 2 diabetes, ... deficiency and the blood sugar disease. In this ... and vitamin D by focusing on genes that control ...
(Date:9/30/2014)... to cut climate-changing carbon emissions will reduce other ... benefits, according to a new study released today. ... options included in the final Clean Power Plan, ... premature deaths and hospitalizations, and hundreds of heart ... the new study, Health Co-benefits of Carbon Standards ...
(Date:9/30/2014)... cancer is the leading cause of cancer death in ... so many medical professionals encourage women to get mammograms, ... a minority of suspicious mammograms actually leads to a ... worry for women and their familiesnot to mention the ... and biopsies. , Recently, a different type of ...
(Date:9/30/2014)... Utah (PRWEB) September 30, 2014 A new ... Ohio State University studied the impact of stress on metabolism ... burger and french fries from a fast food restaurant, about ... woman’s resting metabolism for 20 minutes every hour for 7 ... Results showed that women who had experienced a stressful event ...
(Date:9/30/2014)... 2014 Research by UC Irvine immunologists reveals new ... on a vital process that determines how the body,s ... version of Nature Immunology , neurology professor Dr. ... for Immunology colleagues describe a critical mechanism underlying how ... bloodstream. , A T cell is a type of ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:'Virtual breast' could improve cancer detection 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:UCI study uncovers important process for immune system development 2
... ... Ovid, part of Wolters Kluwer Health and a global leader in ... medical, scientific and academic markets, will be showcasing recent enhancements to ... of a new psychology lexicon, based on the American Psychological Association,s ...
... , The Patient Safety Authority Encourages Older Persons ... Tips Based Upon Authority Data , HARRISBURG, Pa., ... occur in those 65 and older, including residents in nursing ... Authority,s 2009 December Patient Safety Advisory . , According ...
... age are more likely to engage in risky health behaviors ... aging process may act as a disincentive to behave ,sensibly, ... in anticipation of ,miserable, old age. These findings 1 ... Queen,s University Belfast, Northern Ireland, are published online in Springer,s ...
... tied to academic achievement, study finds , TUESDAY, Dec.1 ... adulthood may boost brainpower, making for better school grades ... suggests. , Given that most doctors and laypeople know ... impact on healthy bodies, the authors of a new ...
... , RANCHO SANTA FE, Calif., Dec. 1 ... grapes acclaimed for its potential to forestall the ravages ... (Photo: http://www.newscom.com/cgi-bin/prnh/20091201/NY18305 ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20091111/NY08935LOGO ... ResVez, Inc. of Rancho Santa Fe, Calif. contains as ...
... , , ... At ECPA,s Food Supply Forum, Experts Agree That Adapting Food,Production ... Prof. John Beddington, Chief Scientific Adviser to ... on science and have a,sound evidence basis. "Having a chief ...
Cached Medicine News:Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 2Health News:Ovid Highlights the Latest Productivity Workflow Enhancements to Ovid Universal Search(TM) and its New Psychology Lexicon at London's Online Information 2009 Conference 3Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 2Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 3Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 4Health News:Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 5Health News:Binge drinking youths find getting old a drag 2Health News:Exercise May Lead to a Smarter, More Successful You 2Health News:Exercise May Lead to a Smarter, More Successful You 3Health News:First Resveratrol Nutrition Bar Hits the Market 2Health News:Food Security to be the Top Issue for EU's Science Chief 2
... The Guidant Flextend lead ... pace/sense lead with an ... extendable/retractable helix design offers ... for permanent implantation in ...
... a low profile implantable bipolar fixed ... of either the atrium or the ... with a screwdriver shape stylet which ... The ring tip and fixation screw ...
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Implantable medical grade silicone sleeve for adapting a 5 mm (01) connector to a 6 mm (02) connector....
Medicine Products: